Loading…
A topochemical approach to explain morphiceptin bioactivity
A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic...
Saved in:
Published in: | Journal of medicinal chemistry 1993-03, Vol.36 (6), p.708-719 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3 |
---|---|
cites | |
container_end_page | 719 |
container_issue | 6 |
container_start_page | 708 |
container_title | Journal of medicinal chemistry |
container_volume | 36 |
creator | Yamazaki, Toshimasa Ro, Seonggu Goodman, Murray Chung, Nga N Schiller, Peter W |
description | A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies. |
doi_str_mv | 10.1021/jm00058a007 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75626238</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75626238</sourcerecordid><originalsourceid>FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3</originalsourceid><addsrcrecordid>eNptkMtLAzEQh4MotT5OnoUeRA-ymsfmsXgqRa1SUGw9h2mapam73TXZlfa_N6WlePAUJr9vhpkPoQuC7wim5H5RYoy5AozlAeoSTnGSKpweoi7GlCZUUHaMTkJYRIwRyjqoo5hKhaBd9NDvNVVdmbktnYGiB3XtKzDz-Nuzq7oAt-yVla_nzti6icXUxbhxP65Zn6GjHIpgz3fvKfp8epwMhsno7fll0B8lwBRrEmYUmeUqBykh47lhdCYUwUYZAJZn0xR4amhGp4YAJ6kAZmeZ5BDbKM9TYKfoejs3rvbd2tDo0gVjiwKWtmqDllxsblQRvN2CxlcheJvr2rsS_FoTrDeq9B9Vkb7cjW2npZ3t2Z2bmF_tcghRTe5haVzYY6mkQgoRsWSLudDY1T4G_6WFZJLryftYT0T2-jFmIz2M_M2WBxP0omr9Mrr7d8FfmMGMIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75626238</pqid></control><display><type>article</type><title>A topochemical approach to explain morphiceptin bioactivity</title><source>ACS CRKN Legacy Archives</source><creator>Yamazaki, Toshimasa ; Ro, Seonggu ; Goodman, Murray ; Chung, Nga N ; Schiller, Peter W</creator><creatorcontrib>Yamazaki, Toshimasa ; Ro, Seonggu ; Goodman, Murray ; Chung, Nga N ; Schiller, Peter W</creatorcontrib><description>A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00058a007</identifier><identifier>PMID: 8384662</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Analgesics - chemical synthesis ; Analgesics - chemistry ; Analgesics - pharmacology ; Animals ; Biological and medical sciences ; Computer Simulation ; Endorphins - chemical synthesis ; Endorphins - chemistry ; Endorphins - pharmacology ; Guinea Pigs ; Male ; Medical sciences ; Mice ; Models, Chemical ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Receptors, Opioid - drug effects ; Stereoisomerism ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 1993-03, Vol.36 (6), p.708-719</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm00058a007$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm00058a007$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,778,782,27047,27907,27908,56749,56799</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4726766$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8384662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamazaki, Toshimasa</creatorcontrib><creatorcontrib>Ro, Seonggu</creatorcontrib><creatorcontrib>Goodman, Murray</creatorcontrib><creatorcontrib>Chung, Nga N</creatorcontrib><creatorcontrib>Schiller, Peter W</creatorcontrib><title>A topochemical approach to explain morphiceptin bioactivity</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies.</description><subject>Analgesics - chemical synthesis</subject><subject>Analgesics - chemistry</subject><subject>Analgesics - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Computer Simulation</subject><subject>Endorphins - chemical synthesis</subject><subject>Endorphins - chemistry</subject><subject>Endorphins - pharmacology</subject><subject>Guinea Pigs</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Models, Chemical</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Opioid - drug effects</subject><subject>Stereoisomerism</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNptkMtLAzEQh4MotT5OnoUeRA-ymsfmsXgqRa1SUGw9h2mapam73TXZlfa_N6WlePAUJr9vhpkPoQuC7wim5H5RYoy5AozlAeoSTnGSKpweoi7GlCZUUHaMTkJYRIwRyjqoo5hKhaBd9NDvNVVdmbktnYGiB3XtKzDz-Nuzq7oAt-yVla_nzti6icXUxbhxP65Zn6GjHIpgz3fvKfp8epwMhsno7fll0B8lwBRrEmYUmeUqBykh47lhdCYUwUYZAJZn0xR4amhGp4YAJ6kAZmeZ5BDbKM9TYKfoejs3rvbd2tDo0gVjiwKWtmqDllxsblQRvN2CxlcheJvr2rsS_FoTrDeq9B9Vkb7cjW2npZ3t2Z2bmF_tcghRTe5haVzYY6mkQgoRsWSLudDY1T4G_6WFZJLryftYT0T2-jFmIz2M_M2WBxP0omr9Mrr7d8FfmMGMIw</recordid><startdate>19930319</startdate><enddate>19930319</enddate><creator>Yamazaki, Toshimasa</creator><creator>Ro, Seonggu</creator><creator>Goodman, Murray</creator><creator>Chung, Nga N</creator><creator>Schiller, Peter W</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930319</creationdate><title>A topochemical approach to explain morphiceptin bioactivity</title><author>Yamazaki, Toshimasa ; Ro, Seonggu ; Goodman, Murray ; Chung, Nga N ; Schiller, Peter W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Analgesics - chemical synthesis</topic><topic>Analgesics - chemistry</topic><topic>Analgesics - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Computer Simulation</topic><topic>Endorphins - chemical synthesis</topic><topic>Endorphins - chemistry</topic><topic>Endorphins - pharmacology</topic><topic>Guinea Pigs</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Models, Chemical</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Opioid - drug effects</topic><topic>Stereoisomerism</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamazaki, Toshimasa</creatorcontrib><creatorcontrib>Ro, Seonggu</creatorcontrib><creatorcontrib>Goodman, Murray</creatorcontrib><creatorcontrib>Chung, Nga N</creatorcontrib><creatorcontrib>Schiller, Peter W</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamazaki, Toshimasa</au><au>Ro, Seonggu</au><au>Goodman, Murray</au><au>Chung, Nga N</au><au>Schiller, Peter W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A topochemical approach to explain morphiceptin bioactivity</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1993-03-19</date><risdate>1993</risdate><volume>36</volume><issue>6</issue><spage>708</spage><epage>719</epage><pages>708-719</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>A topochemical model to explain the bioactivity of morphiceptin (Tyr1-Pro2-Phe3-Pro4-NH2) was developed by taking account of accessible conformations around rotatable bonds which define relative spatial arrangements of opioid pharmacophores, the amine and phenolic groups of tyrosine and the aromatic ring of phenylalanine, necessary for receptor recognition. For this purpose, 1H-NMR measurements and computer simulations were extensively carried out on 10 stereoisomeric analogs related to morphiceptin: Tyr-Pro-(L and D)-Phe- (L and D)-Pro-NH2; Tyr-Pro-(L and D)-(NMe)Phe-(L and D)-Pro-NH2; Tyr-(NMe)Ala-Phe-D-Pro-NH2; and Tyr-Ala-Phe-D-Pro-NH2. These analogs are structurally close to one another but display various opiate potencies from highly active to inactive. The conformation of each rotatable bond has been specifically identified by measuring accessible space for the analogs, in which the difference in composition is observed in the specific site affecting only the conformation around the target bond. The most interesting characteristic of the model is a requirement of a cis amide bond linking residues 1 and 2. The model also requires the side chains in a trans conformation (chi 1 = 180 degrees) for the Tyr and Phe residues. The distances between the three pharmacophores, d1 (Tyr N to Tyr OH), d2 (Tyr N to the center of the aromatic ring of the third residue), and d3 (Tyr OH to the center of the aromatic ring of the third residue), were found to be approximately 8, approximately 7, and approximately 11-13 A, respectively. This model should aid in pharmaceutical design of peptide and nonpeptide ligands with opioid potencies.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>8384662</pmid><doi>10.1021/jm00058a007</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1993-03, Vol.36 (6), p.708-719 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_75626238 |
source | ACS CRKN Legacy Archives |
subjects | Analgesics - chemical synthesis Analgesics - chemistry Analgesics - pharmacology Animals Biological and medical sciences Computer Simulation Endorphins - chemical synthesis Endorphins - chemistry Endorphins - pharmacology Guinea Pigs Male Medical sciences Mice Models, Chemical Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems Pharmacology. Drug treatments Receptors, Opioid - drug effects Stereoisomerism Structure-Activity Relationship |
title | A topochemical approach to explain morphiceptin bioactivity |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T01%3A06%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20topochemical%20approach%20to%20explain%20morphiceptin%20bioactivity&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Yamazaki,%20Toshimasa&rft.date=1993-03-19&rft.volume=36&rft.issue=6&rft.spage=708&rft.epage=719&rft.pages=708-719&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm00058a007&rft_dat=%3Cproquest_cross%3E75626238%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a383t-3c81df8fa77a95fc32d6810c8caa3f9b4a54c292bc1a5146a3ed975ac8125f4a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=75626238&rft_id=info:pmid/8384662&rfr_iscdi=true |